Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Matuzumab plus pemetrexed versus pemetrexed alone in previously treated advanced non-small cell lung cancer
2006-000899-32Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Apr 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of matuzumab and pemetrexed in non-small cell lung cancer (NSCLC) (3 arms), sponsored by EMD Serono. Primary endpoint: Tumor response rate. Started Apr 2006; status: completed.
02
Drugs
matuzumabpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-000899-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000899-32.